Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309018034> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4309018034 endingPage "vii38" @default.
- W4309018034 startingPage "vii38" @default.
- W4309018034 abstract "Abstract Tumor Treating Fields (TTFields) are a novel, non-invasive FDA-approved treatment modality for glioblastoma (GBM) that utilises alternating electric fields. Our research aims to elucidate the effect of TTFields on the cell cycle to advance the understanding of TTFields and find novel targets for increasing its efficacy. We studied the cell cycle progression using live-cell imaging (inovitro Live™) of PIP-FUCCI-transduced GBM cells, EdU incorporation, RPA foci and fiber assay (in U251-MG, SNB-19, A172). These tools allow us to track individual cells evaluate the time spent in each cell cycle phase, and study the ultimate cell fate in control and treatment conditions concerning the cell cycle and replication fork dynamics. Statistical testing was performed by 2-way ANOVA, Tukey-corrected for multiple comparisons, and Kruskal-Wallis test. TTFields causes an immediate delay in S and G2 cell cycle phase, with a subsequent G1 arrest. Wee1 inhibition by AZD1775 forces cells through S-phase and abrogates the subsequent TTFields-induced G2-checkpoint, preventing DNA repair. Combined treatment with TTFields and AZD1775 led to decreased incorporation of EdU and an increase in S-phase-specific phospho-RPA foci. TTFields reduced significantly the DNA fiber length after 12, 24, 48 and 72 hrs of exposure (10.2, 8.3, 7.1 and 5.6 vs 13 um), with also an increase in replication fork asymmetry at these time points (0.56, 0.45, 0.49, and 0.47 vs 0.9 ratio) respectively. CombiningTTFields with either Wee1, ATR, or Chk1 inhibition synergistically decreased clonogenic survival. TTFields induced cell cycle effects with the induction of replication stress, which is aggravated by inhibition of Wee1. Additionally, Wee1, ATR, and Chk1 inhibition dramatically boost the efficacy of TTFields in vitro. This combination strategy has promising clinical potential and will be tested in vivo in different GBM xenografts. Cell signaling and signaling pathways" @default.
- W4309018034 created "2022-11-20" @default.
- W4309018034 creator A5008782432 @default.
- W4309018034 creator A5014165324 @default.
- W4309018034 creator A5015714765 @default.
- W4309018034 creator A5034151807 @default.
- W4309018034 creator A5046281929 @default.
- W4309018034 creator A5051901114 @default.
- W4309018034 creator A5069940569 @default.
- W4309018034 creator A5072437007 @default.
- W4309018034 creator A5073245145 @default.
- W4309018034 date "2022-11-01" @default.
- W4309018034 modified "2023-09-30" @default.
- W4309018034 title "CCRG-04. TARGETING THE CELL-CYCLE EFFECTS OF TUMOR TREATING FIELDS (TTFIELDS) TO INCREASE ITS EFFICACY" @default.
- W4309018034 doi "https://doi.org/10.1093/neuonc/noac209.149" @default.
- W4309018034 hasPublicationYear "2022" @default.
- W4309018034 type Work @default.
- W4309018034 citedByCount "0" @default.
- W4309018034 crossrefType "journal-article" @default.
- W4309018034 hasAuthorship W4309018034A5008782432 @default.
- W4309018034 hasAuthorship W4309018034A5014165324 @default.
- W4309018034 hasAuthorship W4309018034A5015714765 @default.
- W4309018034 hasAuthorship W4309018034A5034151807 @default.
- W4309018034 hasAuthorship W4309018034A5046281929 @default.
- W4309018034 hasAuthorship W4309018034A5051901114 @default.
- W4309018034 hasAuthorship W4309018034A5069940569 @default.
- W4309018034 hasAuthorship W4309018034A5072437007 @default.
- W4309018034 hasAuthorship W4309018034A5073245145 @default.
- W4309018034 hasBestOaLocation W43090180341 @default.
- W4309018034 hasConcept C105696609 @default.
- W4309018034 hasConcept C120504264 @default.
- W4309018034 hasConcept C121608353 @default.
- W4309018034 hasConcept C126322002 @default.
- W4309018034 hasConcept C1491633281 @default.
- W4309018034 hasConcept C2781252693 @default.
- W4309018034 hasConcept C29537977 @default.
- W4309018034 hasConcept C502942594 @default.
- W4309018034 hasConcept C54355233 @default.
- W4309018034 hasConcept C71924100 @default.
- W4309018034 hasConcept C86803240 @default.
- W4309018034 hasConceptScore W4309018034C105696609 @default.
- W4309018034 hasConceptScore W4309018034C120504264 @default.
- W4309018034 hasConceptScore W4309018034C121608353 @default.
- W4309018034 hasConceptScore W4309018034C126322002 @default.
- W4309018034 hasConceptScore W4309018034C1491633281 @default.
- W4309018034 hasConceptScore W4309018034C2781252693 @default.
- W4309018034 hasConceptScore W4309018034C29537977 @default.
- W4309018034 hasConceptScore W4309018034C502942594 @default.
- W4309018034 hasConceptScore W4309018034C54355233 @default.
- W4309018034 hasConceptScore W4309018034C71924100 @default.
- W4309018034 hasConceptScore W4309018034C86803240 @default.
- W4309018034 hasIssue "Supplement_7" @default.
- W4309018034 hasLocation W43090180341 @default.
- W4309018034 hasOpenAccess W4309018034 @default.
- W4309018034 hasPrimaryLocation W43090180341 @default.
- W4309018034 hasRelatedWork W2012014075 @default.
- W4309018034 hasRelatedWork W2025951391 @default.
- W4309018034 hasRelatedWork W2087198441 @default.
- W4309018034 hasRelatedWork W2471495136 @default.
- W4309018034 hasRelatedWork W2549574514 @default.
- W4309018034 hasRelatedWork W2588384093 @default.
- W4309018034 hasRelatedWork W2772712893 @default.
- W4309018034 hasRelatedWork W2774956505 @default.
- W4309018034 hasRelatedWork W2892793128 @default.
- W4309018034 hasRelatedWork W4308332201 @default.
- W4309018034 hasVolume "24" @default.
- W4309018034 isParatext "false" @default.
- W4309018034 isRetracted "false" @default.
- W4309018034 workType "article" @default.